5 April 2019 - MSD’s Keytruda (pembrolizumab) has been approved by the European Commission with a new six-weekly dosing schedule at 400 mg, as opposed to the previous schedule of 200mg every three weeks, across all monotherapy indications.

The less frequent dosing gives both patients and oncologists more flexibility, due to less hospital visits which could help chemotherapy nurses and chemotherapy lead consultants by freeing up chair time and infusion suite capacity, and oncology pharmacy by freeing up capacity when infusions are made up in-house.

The humanised monoclonal antibody works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Read Pharma Times article